Key result
A clinical decision aid incorporating CHA2DS2-VASc and HAS-BLED scores along with patient factors was developed to guide optimal antithrombotic therapy for stroke prevention in atrial fibrillation.
A novel clinical decision aid integrating stroke and bleeding risk scores with patient-specific factors provides point-of-care guidance for antithrombotic selection in non-valvular AF that aligns with current guidelines.
Answers are grounded in this paper and cite their sources.
May guide point-of-care antithrombotic decisions in AF; leaves open prospective validation before practice change.
AIMS: The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians. We have developed a clinical decision aid in order to assist clinicians in determining an optimal antithrombotic regime for the prevention of stroke in patients who are newly diagnosed with non-valvular atrial fibrillation. METHODS AND RESULTS: The CHA(2)DS(2)-VASc and HAS-BLED scoring systems were used to assess patients' baseline risks of stroke and major bleeding, respectively. The relative risks of stroke and major bleeding for each antithrombotic agent were then used to identify the agent associated with the lowest net risk. Individual patient factors such as the treatment threshold, bleeding ratio, and cost threshold modified the recommendations in order to generate a final recommendation. By considering both patient factors and clinical research concurrently, this clinical decision aid is able to provide specific advice to clinicians regarding an optimal stroke prevention strategy. The resulting treatment recommendation tables are consistent with the recommendations of the European Society of Cardiology and Canadian Cardiovascular Society Guidelines, which can be incorporated into either a paper-based or electronic format to allow clinicians to have decision support at the point of care. CONCLUSION: The use of a clinical decision aid that considers both patient factors and evidence-based medicine will serve to bridge the knowledge gap and provide practical guidance to clinicians in the prevention of stroke due to atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
LaHaye et al. (2012) studied Non-valvular atrial fibrillation. Clinical decision aid was evaluated on Optimal antithrombotic regime for the prevention of stroke. A clinical decision aid incorporating CHA2DS2-VASc and HAS-BLED scores along with patient factors was developed to guide optimal antithrombotic therapy for stroke prevention in atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: